Asthma
From the Journals
FDA reverses warning on LABA-containing asthma medications
Four trials testing outcomes for patients taking the combination therapy.
From the Journals
Dupilumab reduces exacerbations, cuts glucocorticoid use in moderate to severe asthma
Evidence of lung remodeling was observed in patients with severe asthma in a trial of a anti–interleukin-4 alpha antibody drug.
Conference Coverage
When and how to suspect asthma misdiagnosis
NEW ORLEANS – Lack of symptom variability is a key clue.
Conference Coverage
ED visits higher among pediatric asthma patients with comorbid depression, anxiety
TORONTO – Children with asthma who were on Medicaid also had an independent risk for going to the ED.
Primary Care Medical Abstracts
Abstract: Effect of Oral Prednisolone on Symptom Duration and Severity in Nonasthmatic Adults With Acute Lower Respiratory Tract Infection: A Randomized Clinical Trial
Although symptoms and underlying bronchial hyperresponsiveness are similar in asthma and acute lower respiratory tract infection, guidelines do...
From the Journals
Adjunct treatments assist with persistent asthma
Two meta-analyses support new therapeutic regimens for uncontrolled asthma.
News from the FDA/CDC
Asthma flourishing in its medical home
Prevalence in health care and social assistance workers is well above the national average.
Daily News Podcast
MDedge Daily News: Could gut bacteria trigger lupus?
And acid suppressors in infancy could fuel allergies later on.
Conference Coverage
Switch to mepolizumab safe in eosinophilic asthma
ORLANDO – For patients with severe eosinophilic asthma who do not show improvement with omalizumab, a switch to mepolizumab could be a safe and...
Conference Coverage
Olopatadine/mometasone combo is safe and effective
ORLANDO – Combining two safe and effective options for seasonal allergic rhinitis showed even more efficacy with relative safety.
Conference Coverage
Good definitions, research lacking for COPD-asthma overlap
ORLANDO – Review articles on ACOS outnumber research articles.